Alnylam Pharmaceuticals, Inc. (LON:0HD2)
451.70
+1.69 (0.38%)
At close: Oct 3, 2025
Alnylam Pharmaceuticals Employees
Alnylam Pharmaceuticals had 2,230 employees as of December 31, 2024. The number of employees increased by 130 or 6.19% compared to the previous year.
Employees
2,230
Change (1Y)
130
Growth (1Y)
6.19%
Revenue / Employee
805.82K GBP
Profits / Employee
-104.44K GBP
Market Cap
44.39B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 2,230 | 130 | 6.19% |
Dec 31, 2023 | 2,100 | 98 | 4.90% |
Dec 31, 2022 | 2,002 | 337 | 20.24% |
Dec 31, 2021 | 1,665 | 212 | 14.59% |
Dec 31, 2020 | 1,453 | 130 | 9.83% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
AstraZeneca | 94,300 |
GSK plc | 68,629 |
Haleon | 24,561 |
Smith & Nephew | 17,349 |
ConvaTec Group | 10,489 |
Hikma Pharmaceuticals | 9,500 |
HUTCHMED (China) | 1,811 |
Genus | 3,500 |
Alnylam Pharmaceuticals News
- 3 days ago - Alnylam Pharmaceuticals (ALNY) Pulls Ad After FDA Warning - GuruFocus
- 3 days ago - Alnylam yanks Amvuttra TV ad following FDA letter - report - Seeking Alpha
- 4 days ago - Can Alnylam's Broader Portfolio Ease Its Dependence on Amvuttra? - Nasdaq
- 4 days ago - CGGR, NFLX, ALNY, BAC: ETF Inflow Alert - Nasdaq
- 4 days ago - Alnylam Announces First Patient Dosed in ZENITH Global Phase 3 Cardiovascular Outcomes Trial of Zilebesiran - Business Wire
- 7 days ago - Alnylam (ALNY): Vutrisiran Shows Promise in Reducing Gastrointestinal Events - GuruFocus
- 7 days ago - New Data from HELIOS-B Phase 3 Study Demonstrate Lower Rates of Gastrointestinal Events in ATTR-CM Patients Treated with Vutrisiran - Business Wire
- 9 days ago - $1000 Invested In Alnylam Pharmaceuticals 5 Years Ago Would Be Worth This Much Today - Benzinga